Drugs /

bintrafusp alfa

Back to Drugs List

Overview

NCI Definition [1]:
A bifunctional fusion protein composed of avelumab, an anti-programmed death ligand 1 (PD-L1) human monoclonal antibody, bound to the soluble extracellular domain of human transforming growth factor beta (TGFbeta) receptor type II (TGFbetaRII), with potential antineoplastic and immune checkpoint modulating activities. Upon administration, the TGFbetaRII moiety of bintrafusp alfa binds to and neutralizes TGFbeta while the avelumab moiety simultaneously binds to PD-L1. This prevents TGFbeta- and PD-L1-mediated signaling, and increases natural killer (NK) cell and cytotoxic T-lymphocyte (CTL) activities. This inhibits tumor cell proliferation in susceptible tumor cells. TGFbeta and PD-L1 are both upregulated in certain types of cancers; their overexpression is associated with increased evasion of immune surveillance and contributes to poor prognosis.

Clinical Trials

View Clinical Trials for bintrafusp alfa

Bintrafusp alfa has been investigated in 42 clinical trials, of which 40 are open and 2 are closed. Of the trials investigating bintrafusp alfa, 12 are phase 1 (12 open), 16 are phase 1/phase 2 (14 open), 12 are phase 2 (12 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open).

HER2 Deficient Expression, HER2 Negative, and CDKN2A Overexpression are the most frequent biomarker inclusion criteria for bintrafusp alfa clinical trials.

Malignant solid tumor, breast carcinoma, and non-small cell lung carcinoma are the most common diseases being investigated in bintrafusp alfa clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bintrafusp Alfa
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Bintrafusp Alfa
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bintrafusp alfa and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
msb0011359c, m7824, anti-pdl1/tgfb trap msb0011359c, anti-pd-l1/tgfbetarii fusion protein m7824
Drug Target(s) [2]:
CD274, TGFB1
NCIT ID [1]:
C124229

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.